Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
  • C07J53/002—Carbocyclic rings fused
  • C07J53/004—3 membered carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/26—Androgens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/34—Gestagens

Definitions

• the invention relates to new unsaturated 14 , 15 -cyclopropane-androstanes 14 , 15 -cyclopropanoandrostanes, a method for their production and pharmaceutical compositions containing these compounds.
• Unsaturated 14 , 15 -cyclopropane-androstanes 14 , 15 -cyclopropanoandrostanes of the following formula: are described in the German application Patent Application No. 198 27 523.4 (PCT/DE99/01794), which claims a priority earlier than that of the present application, but was published after the latter was filed.
• R 1 is a hydrogen atom, a hydroxy group, an alkyloxy group, an acyloxy group, alryloxy an aryloxy group, or an alkylaryloxy group, an —OCONHR 9 , or —OCOOR 9 group, in which R 9 represents a hydrogen atom, an alkyl group, an aryl group, an aralkyl group, or alkylaryl group with, in each case, 1 to 10 carbon atoms, ;
• steroids are known with at 14 , 15 methylene at 14 , 15 -methylene group, which have progesterone activity and, with that, in combination with at least one suitable estrogen, are suitable for hormonal contraception and menopausal hormone replacement therapy (HRT) as well as for the treatment of endometriosis and or gestagen-dependent tumors.
• HRT menopausal hormone replacement therapy
• R 1 represents a hydrogen atom, a hydroxy group, a C 1-10 alkyl group, a C 1-10 alkyloxy group, a C 1-15 acyloxy group, a C 4-15 aryloxy group, a C 7-15 aralkyloxy group, or a C 7-15 alkylaryloxy group, in which ;
• the inventive, unsaturated 14 , 15 -cyclopropane-androstanes 14 , 15 -cyclopropanoandrostanes of the general formula (I) are compounds with gestagenic and/or androgenic activity.
• pharmaceutically tolerated salts are alkali or alkaline earth salts, especially sodium, potassium or ammonium salts. These salts can be synthesized by standard techniques and methods, which are well known in the art.
• a “C 1-4 or C 1-10 alkyl group” is understood to be a branched or linear alkyl group with 1 to 4 or 1 to 10 carbon atoms.
• a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl, n-pentyl, i-pentyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl or 2,3-dimethylbutyl group are mentioned.
• C 1-10 alkoxy group is understood to include cyclic or acyclic groups, the alkyl portion of which contains 1 to 10 carbon atoms.
• Cyclic groups are understood to include also heterocyclic groups, which may have one or two hetero atoms in the ring, which may be selected from a nitrogen atom, an oxygen atom and a sulfur atom.
• a methoxy group, an ethoxy group or an n- or iso-propoxy group or an iso- or t-butoxy, a 1′-methoxy-cyclopentoxy or a tetrahydropyranyloxy group are examples.
• C 1-10 or C 1-15 acyl or acyloxy group is understood to be a group with 1 to 10 or 1 to 15 carbon atoms of the linear or branched alkane carboxylic acids, such as formic acid, acetic acid, propionic acid, butyric acid, iso-butyric acid, heptanoic acid or undecanoic acid.
• C 6-15 aryl group is understood to include a substituted or unsubstituted aryl group with 6 to 15 carbon atoms, such as a phenyl group, a substituted phenyl group, such as a halogenated phenyl group or a nitrophenyl group, or a naphthyl group.
• C 4-15 aryloxy group is understood to include a carbocyclic or heterocyclic group with 4 to 15 carbon atoms. Examples are a benzoyloxy group, a 1- or 2-naphthinyloxy group, a 2- or 3-furanyloxy group, a 2- or 3-thienyl group and a 2-, 3- or 4-pyridinyloxy group.
• C 7-15 alkylaryl group is understood to include an aryl group, which is substituted by an alkyl group, the two group together having 7 to 15 carbon atoms.
• the aryl group may have additional substituents, such as a halogen atom. Examples are a toluenyl group (methylphenyl group), a halogenated toluenyl group, an ethylphenyl group, a dimethylphenyl group or a trimethylphenyl group.
• C 7-15 alkylaryloxy group is understood to be a “C 7-15 aralkyl group”, such as a 3- or a 4-methylphenyloxy group, which is extended by an oxygen atom.
• C 7-15 aralkyl group is understood to include an alkyl group, which is substituted by an aryl group, the two groups together having 7 to 15 carbon atoms.
• the aryl group may have further substituents, such as a halogen atom. Examples are a free or an aromatically substituted benzyl group, such as a benzyl group or a halogenated benzyl group.
• C 7-15 aralkyloxy group is understood to include “C 7-15 aralkyl groups”, which has been extended by an oxygen atom, such as a benzyloxy group.
• halogen comprises a fluorine, chlorine, bromine or iodine atom.
• pseudohalogen comprises a cyanate, rhodanide, cyanato, thiocyanato, cyano, or azide azido group.
• perfluoroalkyl group comprises a branched or linear fluoroalkyl group with 1 to 3 carbon atoms, such as a trifluoromethyl, pentafluoroethyl, heptafluoro-n-propyl or heptafluoro-i-propyl group.
• R 1 represents preferably a hydroxy or acyloxy group, especially a hydroxy group, formyloxy group, acetyloxy group, propionyloxy group, n-butyryloxy group, i-butyryloxy group, heptanyloxy group or undecanyl group.
• R 2 represents a —(CH 2 ) n CH 2 Y group
• n preferably is 1 and Y preferably represents a fluorine atom, a cyano or rhodanide group.
• R 2 is a —(CH 2 ) m —CH ⁇ CH(CH 2 ) p —R 6 group
• m preferably is 1 and R 6 preferably represents a methyl or ethyl group or a methoxy or ethoxy group.
• R 2 represents a —(CH 2 ) o C ⁇ CR 7 group
• o preferably is 1 and R 7 preferably represents a fluorine atom, a methyl group, or an ethyl group.
• R 2 represents a hydrogen atom or a C 1-6 alkyl group, especially a methyl or ethyl group.
• R 3 preferably represents a C 1-4 alkyl group, especially a methyl group.
• R 4 preferably represents a fluorine, chlorine or bromine atom or a trifluormethyl or hydroxy group.
• R 5 preferably represents a methyl or ethyl group.
• inventive compounds and their pharmaceutically acceptable salts can be synthesized in that, in compounds of the general formula (II) in which R 1 , R 2 , R 3 , and R 5 , which have the meanings given above, and there is an ⁇ or ⁇ cyclopropane group between C-14 and C-15, the 4,5 double bond is epoxidized under alkaline conditions with hydrogen peroxide and the resulting epoxide mixture is treated in a suitable solvent with acids of the general formula HR 8 , in which R 8 may be a halogen atom or a pseudohalogen.
• the corresponding 4-bromo compounds can also be synthesized by the addition of bromine by means of bromine, N-bromosuccinimide or N-bromoacetamide to compounds of the general formula (II) in a mixture of acetic acid and ether in the presence of a proton acceptor, such as collidine, (X. S. Fei et. al., J. Chem. Soc. Perkin Trans. 1, 1998, 1139-1142).
• 4-Hydroxy compounds are obtained by reacting the epoxide mixture above with catalytic amounts of mineral acid, such as sulfuric acid (P. S. Furth et. al. J. Enzyme Inhibition, 1990, Vol. 4, 131-135).
• mineral acid such as sulfuric acid
• 4-Trifluormethyl compound of the general formula (I) can be obtained by the reaction of the 4-bromo compounds of the general formula (I), which are mentioned above, with methyl 2,2-difluoro-2-(fluorosulfonyl)acetate in dimethylformamide the presence of CuI (X. S. Fei et. al., J. Chem. Soc., Perkin Trans. 1, 1998, 1139-1142).
• the starting compounds of formula (II) can be synthesized by known methods or by the method described in the German application with the application No. 198 27 523.4 (PCT/DE99/01794).
• the introduction of the groups, which are analogous to the groups R 1 , R 2 , R 3 and R 5 occurring there and are claimed here, is described in the protective right mentioned.
• compositions for the oral, rectal, subcutaneous, intravenous or intramuscular applications which contain at least one compound of the general formula (I) and/or their acid addition salts as active ingredient, together with the conventional vehicles and diluents are also an object of the present invention.
• compositions of the invention are prepared with the usual solid or liquid vehicles and/or diluents and the inactive ingredients, the use of which is generally customary in accordance with the desired type of application, in a suitable dosage and by a known procedure.
• a preferred oral form of administration preferably tablets, film-coated tablets, coated tablets, capsules, pills, powders, solutions or suspensions are prepared also in sustained release form.
• parenteral forms of medicinal drugs such as injection solutions or suspensions, can also be considered.
• Medicinal drug forms as tablets can be obtained for example by mixing the active ingredient with the known inert materials, such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc and/or agents, which can achieve a sustained release effect, such as carboxypolymethylene, carboxymethylcellulose, cellulose acetate phthalate or polyvinyl acetate.
• the tablets may also consist of several layers.
• coated tablets can be prepared by coating cores, prepared similarly to the tablets, with agents used in conventional tablet coatings, such as polyvinylpyrrolidone or shellac, gum arabic, talc, titanium dioxide or sugar.
• the tablet coating may consist of several layers, the inert materials, named above, for example being used.
• the solutions or suspensions with the inventive active ingredient can be mixed with materials such as saccharin, cyclamate or sugar and/or with aromatic and flavoring materials such as vanillin or orange extract. Moreover, they may be mixed with suspending agents, such as sodium carboxymethylcellulose, or preservatives, such as p-hydroxybenzoic acid.
• Capsules can be prepared by mixing medicinal drugs with vehicles, such as lactose or sorbitol, which are then brought into the capsules.
• vehicles such as lactose or sorbitol
• Suppositories are prepared preferably by mixing active ingredients with suitable vehicles, such as neutral fats or polyethylene glycols or their derivatives.
• the pharmaceutical forms of preparations furthermore can be percutaneous forms, such as transdermal therapeutic systems (TTS) or gels, sprays or ointments or intranasal forms, such as nose sprays or oral nose drops.
• TTS transdermal therapeutic systems
• intranasal forms such as nose sprays or oral nose drops.
• the inventive 14,15-cyclopropanoandrostanes of the general formula (I) are compounds with hormonal (gestagenic and/or androgenic) activity.
• the 4-chloro-17 ⁇ -hydroxy-14 ⁇ ,15 ⁇ -methylene-androst-4-ene-3-one binds to the extent of 42% ⁇ 3% to the androgen receptor of the rat prostate (reference substance. 17 ⁇ -hydroxy-17 ⁇ -methyl-estra-4,9,11-triene-3-one; R 1881).
• progesterone progesterone
• 17 ⁇ -hydroxy-14 ⁇ ,15 ⁇ -methylene-androst-4-ene-3-one (2 g) is dissolved in 80 mL of methanol and treated at 0° C. with 26 mL of a hydrogen peroxide solution (35%). While stirring, 5.2 mL of a 10% sodium hydroxide solution are added, the stirring being continued at 0° C. for 30 hours.
• the reaction solution is mixed with 50 mL of dichloromethane and 25 mL of water and the organic phase is removed, washed with semi-concentrated thiosulfate solution, dried and evaporated to dryness.
• the residue obtained consists of a mixture of 4 ⁇ ,5 ⁇ - or 4 ⁇ ,5 ⁇ -epoxides and is used in the subsequent step without further purification.
• the compound, named above, can be obtained from 17 ⁇ -hydroxy-14 ⁇ ,15 ⁇ -methylene-androst-4-ene-3-one by a method, similar to that of Example 1.
• 17 ⁇ -hydroxy-4,5-epoxy-14 ⁇ ,15 ⁇ -methylene-androstan-3-one (1.5 g) is dissolved in 150 mL of acetone and treated at 0° C. with 5.5 mL of concentrated hydrochloric acid. After 24 hours at 0° C., the reaction mixture is neutralized with sodium carbonate solution and the acetone is evaporated. The residue is extracted with dichloromethane. The organic extracts are dried and concentrated. After crystallization from ethanol, 4-chloro-17 ⁇ -hydroxy-14 ⁇ ,15 ⁇ -methylene-androst-4-ene-3-one is obtained.
• step 1 An epoxide mixture (3.5 g), 17 ⁇ -hydroxy-4,5-epoxy-14 ⁇ ,15 ⁇ -methylene-androstan-3-one, (step 1) is dissolved in 50 mL of acetic acid, which contains 2% by volume of concentrated sulfuric acid. The solution is allowed to stand for 3 days at 10° C. After that, it is treated with 200 mL ethyl acetate and neutralized with sodium carbonate solution. The organic phase is dried and concentrated. The residue is dissolved in 100 mL of methanol, treated with 4 g of potassium hydroxide, refluxed for 1 hour and then cooled. After neutralization with 50% acetic acid, it is poured into 1 L of water and the crystals are filtered off with suction, 4,17 ⁇ -Dihydroxy-14 ⁇ ,15 ⁇ -methylene-androst-4-ene-3-one being obtained.
• the target compound is synthesized in a manner similar to the synthesis of 4-Chloro-17 ⁇ -hydroxy-14 ⁇ ,15 ⁇ -methylene-androst-4-ene-3-one, 48% hydrobromic acid being used instead of hydrochloric acid.
• 4-Bromo-17 ⁇ -hydroxy-14 ⁇ ,15 ⁇ -methylene-androst-4-ene-3-one (1.5 g) is dissolved in 180 mL of dimethylformamide and stirred at 75° C. for 12 hours with 1 g of CuI as well as 2.8 mL of methyl 2,2-difluoro-2-(fluorosulfonyl) acetate. After working up and chromatographic purification, 4-Trifluoromethyl-17 ⁇ -hydroxy-14 ⁇ ,15 ⁇ -methylene-androst-4-ene-3-one is obtained.
• This compound is prepared from 4-chloro-17 ⁇ -hydroxy-14 ⁇ ,15 ⁇ -methylene-androst-4-ene-3-one by a method to that of Example 6.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Endocrinology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Diabetes (AREA)
• Reproductive Health (AREA)
• Gynecology & Obstetrics (AREA)
• Pregnancy & Childbirth (AREA)
• Steroid Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Applications Claiming Priority (2)

Related Parent Applications (1)

Publications (1)

Family

ID=7932216

Family Applications (2)

Family Applications After (1)

Country Status (26)

Families Citing this family (1)

Citations (12)

• 1999
  • 1999-12-08 DE DE19959696A patent/DE19959696A1/de not_active Ceased
• 2000
  • 2000-11-21 CZ CZ20022005A patent/CZ20022005A3/cs unknown
  • 2000-11-21 RU RU2002117425/04A patent/RU2244718C2/ru not_active IP Right Cessation
  • 2000-11-21 WO PCT/EP2000/011557 patent/WO2001042275A1/de active IP Right Grant
  • 2000-11-21 CN CNB008188556A patent/CN1205219C/zh not_active Expired - Fee Related
  • 2000-11-21 AU AU17038/01A patent/AU774384B2/en not_active Ceased
  • 2000-11-21 AT AT00979607T patent/ATE275576T1/de not_active IP Right Cessation
  • 2000-11-21 KR KR10-2002-7007365A patent/KR100468341B1/ko not_active IP Right Cessation
  • 2000-11-21 PT PT00979607T patent/PT1235850E/pt unknown
  • 2000-11-21 JP JP2001543572A patent/JP3793088B2/ja not_active Expired - Fee Related
  • 2000-11-21 DK DK00979607T patent/DK1235850T3/da active
  • 2000-11-21 US US11/008,758 patent/USRE39862E1/en not_active Expired - Fee Related
  • 2000-11-21 DE DE50007708T patent/DE50007708D1/de not_active Expired - Fee Related
  • 2000-11-21 IL IL15008200A patent/IL150082A0/xx active IP Right Grant
  • 2000-11-21 MX MXPA02005644A patent/MXPA02005644A/es active IP Right Grant
  • 2000-11-21 HU HU0203655A patent/HUP0203655A3/hu unknown
  • 2000-11-21 BR BR0016737-1A patent/BR0016737A/pt not_active Application Discontinuation
  • 2000-11-21 US US10/148,157 patent/US6710039B1/en not_active Ceased
  • 2000-11-21 ES ES00979607T patent/ES2226949T3/es not_active Expired - Lifetime
  • 2000-11-21 PL PL00356061A patent/PL356061A1/xx not_active Application Discontinuation
  • 2000-11-21 EP EP00979607A patent/EP1235850B1/de not_active Expired - Lifetime
  • 2000-11-21 EE EEP200200302A patent/EE200200302A/xx unknown
  • 2000-11-21 SI SI200030553T patent/SI1235850T1/xx unknown
  • 2000-11-21 CA CA002393758A patent/CA2393758C/en not_active Expired - Fee Related
  • 2000-11-21 SK SK809-2002A patent/SK8092002A3/sk unknown
• 2002
  • 2002-06-06 IL IL150082A patent/IL150082A/en not_active IP Right Cessation
  • 2002-06-07 NO NO20022712A patent/NO323376B1/no unknown
  • 2002-06-24 BG BG106861A patent/BG106861A/bg unknown
  • 2002-07-04 ZA ZA200205362A patent/ZA200205362B/xx unknown

Patent Citations (13)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events